<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="512">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>23/09/2005</approvaldate>
  <actrnumber>ACTRN12605000489695</actrnumber>
  <trial_identification>
    <studytitle>A prospective double blind randomised clinical trial of 70% ethanol to treat proven or suspected catheter related sepsis in haematology patients.</studytitle>
    <scientifictitle>A prospective double blind randomised clinical trial of 70% ethanol to treat proven or suspected catheter related sepsis in haematology patients.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Proven or suspected central venous catheter sepsis.</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Routine antimircobials with the additon of daily 2 hourly locks of 70% ethanol.  This intervention/control will continue until a clinical decision is made to stop the antimircobials.</interventions>
    <comparator>control (haparin / saline) instilled into the lumen of the central venous catheter</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the efficiacy of ethanol in the teatment of proven and suspected catheter related sepsis. </outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Primary endpoint will be resolution of symptoms and signs of sepsis.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Prevention of recurrence of catheter related sepsis.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Proven catheter related sepsis (same organism in both the peripheral blood and central line culture or from the FAS brush).  Suspected CRS &gt; 1000 organisms in either FAS sample or Central line blood culture. Consents to participate in the trial Haematological Malignancy Bone Marrow Transplantation. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known allergy to Ethanol Elevated LFTs (2.5 times above the upper normal range).  Known history of Alcoholism.  Pregnant of lactating women,  Positive cultures both peripherally and centrally but NOT the same organism.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>There was one unblinded pharmacist who kept the randomsations in a different department to where the study was being conducted.  Randomsation occurred by fax.</concealment>
    <sequence>Sequence generation was performed using Mircosoft Excel</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/04/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Alan Pithie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Upper Southern Region Ethics committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Joanne Sanders</name>
      <address>Canterbury Health Labs
PO Box 151
Christchurch 8001</address>
      <phone>+64 3 3640377</phone>
      <fax>+64 3 3640750</fax>
      <email>joanne.sanders@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Alan Pithie</name>
      <address>Christchurch Hospital
PO Box 4710
Christchurch</address>
      <phone>+64 3 3640640</phone>
      <fax />
      <email>alan.pithie@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>